GLP-1 and Mood Changes: Can Wegovy or Zepbound Affect Your Mental Health?

The Mood Question Seniors Are Asking

As millions of Americans begin GLP-1 medications through Medicare's new coverage, an important question is gaining attention: can these drugs affect your mood? Reports of depression, anxiety, and emotional changes in some patients have prompted the FDA, the European Medicines Agency (EMA), and researchers worldwide to investigate the connection between GLP-1 receptor agonists and mental health.

For seniors — who already face higher rates of depression and social isolation — understanding this potential side effect is especially important.

What the FDA and EMA Have Found

In January 2024, the FDA completed a safety review of suicidal thoughts and behaviors in patients taking GLP-1 receptor agonists including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). The agency concluded that the available evidence 'does not indicate these medicines cause suicidal thoughts or actions,' but noted it would continue monitoring reports.

The European Medicines Agency conducted a parallel review and reached a similar conclusion in 2024, stating there was 'no causal association established' between GLP-1 agonists and suicidality based on current data.

However, both agencies acknowledged that individual patients have reported mood changes, and that post-marketing surveillance — tracking side effects after a drug reaches the general population — is ongoing.

What the Research Shows

A large 2024 observational study published in Nature Medicine analyzed health records of over 240,000 patients taking semaglutide and found that the medication was associated with a lower risk of new depression diagnoses compared to non-GLP-1 anti-obesity medications. The study, led by researchers at Case Western Reserve University, suggested that GLP-1 medications might even have mood-protective effects for some patients.

Dr. Rong Xu, a professor of biomedical informatics at Case Western, noted that 'the GLP-1 receptor is expressed in brain regions involved in mood regulation, and preclinical studies suggest these drugs may have neuroprotective and anti-inflammatory effects in the central nervous system.'

A separate 2023 meta-analysis in the journal Diabetes, Obesity and Metabolism reviewed 25 clinical trials and found no statistically significant increase in depression or anxiety among GLP-1 users compared to placebo groups.

Why Some People Still Experience Mood Changes

Despite the reassuring population-level data, individual experiences vary. Several factors can explain why some seniors notice mood changes after starting a GLP-1:

• Rapid dietary changes: Eating significantly less can affect energy levels, blood sugar stability, and neurotransmitter production — all of which influence mood
• Social and emotional aspects of food: For many seniors, meals are a primary social activity. Losing interest in food can lead to isolation and reduced enjoyment of daily life
• Nutritional deficiencies: Reduced food intake can lead to deficiencies in B vitamins, iron, folate, and omega-3 fatty acids — all linked to mood regulation
• Existing mental health conditions: Seniors with a history of depression or anxiety may be more sensitive to the physiological changes caused by rapid weight loss
• Fatigue and low energy: Common GLP-1 side effects like nausea and reduced appetite can cause fatigue, which is often experienced as low mood

Warning Signs to Watch For

While serious psychiatric side effects appear to be rare, you should monitor your mental health after starting a GLP-1 medication. Contact your doctor promptly if you experience:

• Persistent sadness or feelings of emptiness lasting more than two weeks
• Loss of interest in activities you previously enjoyed
• Significant changes in sleep patterns — sleeping much more or much less than usual
• Withdrawal from family, friends, or social activities
• Feelings of worthlessness, excessive guilt, or hopelessness
• Thoughts of self-harm or suicide — call 988 (Suicide and Crisis Lifeline) immediately

Protecting Your Mental Health on a GLP-1

Proactive steps can help maintain emotional well-being while taking a GLP-1 medication:

• Keep a simple mood journal — note your energy and emotional state daily for the first three months so you can identify patterns
• Maintain social connections around food — even if you eat less, continue sharing meals with family and friends
• Prioritize protein and nutrient-dense foods to prevent deficiencies that affect mood
• Stay physically active — even 20 minutes of walking daily has been shown to reduce depression risk in seniors
• Talk to your doctor about screening for depression at your follow-up appointments
• If you are already taking an antidepressant, do not change your dose without consulting your prescriber

The Emotional Side of Rapid Weight Loss

An often-overlooked aspect of GLP-1 treatment is the emotional impact of rapid body changes. Dr. Carolyn Becker, a psychologist at Trinity University who specializes in body image, has written that 'significant weight loss — even when desired — can trigger complex emotions including grief, identity confusion, and anxiety about maintaining the loss.'

For seniors who have carried extra weight for decades, the physical transformation can be disorienting. Clothes no longer fit. Friends and family comment on your appearance. Your relationship with food — a lifelong companion — fundamentally shifts. These are normal psychological responses to major life changes, not signs that something is wrong with you.

Talk to Your Doctor Before Starting

If you have a history of depression, anxiety, bipolar disorder, or any mental health condition, share this information with your doctor before starting a GLP-1 medication. Your prescriber can establish a baseline mental health assessment and create a monitoring plan tailored to your needs.

Related Articles

• GLP-1 Side Effects Seniors Should Know Before Starting
• What to Expect at Your First GLP-1 Appointment on Medicare
• What to Eat on a GLP-1 When Your Appetite Disappears
• How to Prevent Muscle Loss on GLP-1 Medications When You Are Over 60

Sources

• U.S. Food and Drug Administration. 'FDA Reports No Evidence of Suicidal Thoughts From GLP-1 Receptor Agonists.' fda.gov, January 2024
• European Medicines Agency. 'GLP-1 Receptor Agonists: No Causal Association With Suicidality.' ema.europa.eu, 2024
• Xu R, et al. 'Association of Semaglutide With Reduced Incidence of Depression.' Nature Medicine, 2024
• Wang W, et al. 'GLP-1 Receptor Agonists and Psychiatric Outcomes: A Systematic Review and Meta-Analysis.' Diabetes, Obesity and Metabolism, 2023
• Becker CB. 'Psychological Impacts of Significant Weight Loss in Adults.' Trinity University Department of Psychology, 2023